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Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by selective degeneration of
dopaminergic neurons in the substantia nigra (SN). The familial form of PD, PARK2, is caused by mutations in the
parkin gene. parkin-knockout mouse models show some abnormalities, but they do not fully recapitulate the
pathophysiology of human PARK2.
Results: Here, we generated induced pluripotent stem cells (iPSCs) from two PARK2 patients. PARK2 iPSC-derived
neurons showed increased oxidative stress and enhanced activity of the nuclear factor erythroid 2-related factor 2
(Nrf2) pathway. iPSC-derived neurons, but not fibroblasts or iPSCs, exhibited abnormal mitochondrial morphology
and impaired mitochondrial homeostasis. Although PARK2 patients rarely exhibit Lewy body (LB) formation with an
accumulation of α-synuclein, α-synuclein accumulation was observed in the postmortem brain of one of the donor
patients. This accumulation was also seen in the iPSC-derived neurons in the same patient.
Conclusions: Thus, pathogenic changes in the brain of a PARK2 patient were recapitulated using iPSC technology.
These novel findings reveal mechanistic insights into the onset of PARK2 and identify novel targets for drug
screening and potential modified therapies for PD.
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Parkin is a causative gene of autosomal recessive juvenile
Parkinson’s disease (PARK2). It encodes a component of
an E3 ubiquitin ligase involved in mitochondrial homeo-
stasis [1-5]. Parkin deficiency is thought to result in ab-
errant ubiquitination and compromised mitochondrial
integrity, leading to neuronal dysfunction and degener-
ation. Several PARK2 mouse models exist, but they do* Correspondence: hidokano@a2.keio.jp
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reproduction in any medium, provided the ornot replicate all of the pathogenic changes seen in
human PARK2 neurons; thus, these models do not fully
account for the molecular mechanisms of PD [6-9]. A
recent report demonstrated that there is a defect in
dopamine (DA) utilization in PARK2 induced pluripo-
tent stem cell (iPSC)-derived neurons [10]. However, it
is not known whether neuronal homeostasis is disrupted
in PARK2 patients. Furthermore, studies have yet to
demonstrate whether the phenotype of PD-specific
iPSC-derived neurons recapitulates the in vivo pheno-
type of the corresponding cell donor. To address these
questions, we generated iPSCs from two PARK2 patientsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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not PARK2 fibroblasts or iPSCs, abnormal mitochondrial
morphology and aberrant tubulovesicular structures ad-
jacent to the Golgi were observed, as was increased oxi-
dative stress. Although α-synuclein accumulation and
Lewy body (LB) formation are very rare in PARK2
patients [1,12,13], we observed pathological changes and
prominent LB formation, including the accumulation of
α-synuclein, in postmortem brain tissue from one of the
donor patients (PA). However, we obtained autopsied
brain tissue from the father of donor PB, who carried
the same parkin deletion as PB, and observed no evi-
dence of LB formation or α-synuclein-positive cells.
Consistent with these observations in postmortem brain
tissue, increased α-synuclein accumulation was clearly
observed in PA iPSC-derived neurons in vitro, but not in
PB iPCS-derived neurons. These results are the first
demonstration of pathogenic changes in the brain of a
PARK2 patient that were recapitulated using iPSC tech-
nology. Our findings also provide mechanistic insights
into PARK2 pathophysiology.
Results & discussion
Generation of PARK2 iPSCs
iPSCs were generated from dermal fibroblasts isolated from
two PARK2 patients carrying parkin mutations and two
control subjects using retroviruses carrying Oct4, Sox2,
Klf4, and c-Myc to reprogram the cells as previously
described [14,15]. The PARK2 patients were a 71-year-old
female (PA) with a homozygous deletion of parkin exons
2–4 and a 50-year-old male (PB) with a homozygous dele-
tion of exons 6 and 7 (Table 1 and Additional file 1A and
B). Patient PA died 1 year after enrollment in the study at
the age of 72. A previously-established human iPSC clone
from control subject A, 201B7 (B7), was also used [15]. In
addition, the following human embryonic stem cell (hESC)-
like iPSC clones were selected for detailed analysis: three
controls (B7 and YA9 from control A, and WD39 from
control B), three from patient PA (PA1, PA9 and PA22),
and four from patient PB (PB1, PB2, PB18 and PB20)
(Figure 1A and Additional file 2A and B).
The PARK2 iPSCs expressed pluripotent hESC markers
(Figure 1A and Additional file 2A-C) and formed terato-
mas containing all three germ layers (Additional file 2D).Table 1 PA and PB patient information
PA patient PB patient
Race Japanese Japanese
Age 72 y/o 50 y/o
Sex Female Male
Age of onset 62 y/o 28 y/o
Mutation of
parkin
Exon 2–4 homozygous
deletions
Exon 6, 7 homozygous
deletionsAll of the retroviral transgenes were silenced in each clone
(Additional file 2E). The iPSCs derived from PA and PB
retained the corresponding homozygous parkin deletions
and exhibited genomic stability (Figure 1B-D; Additional
file 3A and B; and Table 1). All of the clones differentiated
into neurons, including tyrosine hydroxylase (TH)-positive
neurons, through a process of embryoid body and neuro-
sphere formation (Figure 1A). Thus, all of the lines were
successfully reprogrammed into a pluripotent state and
were suitable for further analysis.Increased oxidative stress accompanied by activation of
the Nrf2 pathway in PARK2 iPSC-derived neurons
Because increased levels of oxidative stress have been
documented in other PD models [7,10,16,17], we exa-
mined oxidative metabolism in the iPSC clones by mea-
suring the cellular levels of reduced glutathione (GSH).
GSH reacts with reactive oxygen species (ROS) and is ca-
talyzed by glutathione S-transferase[18]. Consistent with
previous results from patient-derived cells [16], the levels
of GSH in PARK2 iPSC-derived neurospheres were signifi-
cantly lower than those in control iPSC-derived neuro-
spheres (Figure 2A). We also examined ROS production
using 2’, 7’-dichlorodihydrofluorescin (DCF) fluorescence
to measure the levels of intracellular oxidants. The DCF
fluorescence intensity in the PARK2 iPSC-derived
neurons was significantly higher than that in control
iPSC-derived neurons (Figure 2B and C), which indi-
cated an increased level of oxidative stress. A recent
study showed that, in PARK2 iPSC-derived neurons,
monoamine oxidase (MAO)-A and -B levels and oxi-
dative stress levels are increased, as is spontaneous
DA release [10]. Here, we found no significant dif-
ferences in MAO-A and -B expression levels be-
tween PARK2 and control neurons (Additional file
4A and B).
The Nrf2 pathway plays a cytoprotective role under
conditions of ROS accumulation. Recent studies show that
activation of the Nrf2 pathway reduces oxidative stress and
provides partial protection from MPTP-mediated neuro-
toxicity[19]. Elevated Nrf2 expression was observed in the
postmortem brain of a PD patient [20]. These data suggest
a putative link between the Nrf2 pathway and PD, and
prompted a closer investigation of this signaling pathway in
control and PARK2 iPSC-derived neurons [19-21]. The ex-
pression of Nrf2 pathway proteins, such as Nrf2 and
NADH quinone oxidoreductase (NQO1), was significantly
increased in PARK2 iPSC-derived neurons (Figure 2D
and E). These data are in line with previous reports
[19-21], and suggest that the Nrf2 cytoprotective path-
way may be activated in PARK2 iPSC-derived neurons
to prevent further damage from oxidative stress. Taken
together, these data demonstrated an increased level of
Figure 1 Generation of PARK2 iPSCs. (A) iPSCs derived from control and PARK2 subjects, embryoid bodies (EBs), neurospheres (NSs), and
neurons. Left three rows: iPSCs from Control A (YA9), Control B (WD39), PA (PA9), and PB (PB2) were immunopositive for the pluripotency markers
Oct4 (green) and Nanog (red). Right three rows: Differentiation of iPSCs into tyrosine hydroxylase (TH)-positive (red) neurons via EB and NS
formation. Scale bars: Phase contrast, 400 μm; Nanog and Oct4 immunostaining, 100 μm; EBs, 25 μm; NSs, 50 μm; neurons, 10 μm. (B) Deletion of
exons 2–4 in clones PA1, 9 and 22; and of exons 6 and 7 in clones PB1, 2, 18, and 20 was confirmed. (C) Exons 2–4 were deleted in human
dermal fibroblasts (HDFs) from PA and in PA1 iPSC lines. Exons 6 and 7 were deleted in HDFs from PB and PB1 iPSC lines. (D) Copy number
profiles of whole chromosomes in PARK2 HDFs and iPSCs were assessed by comparative genomic hybridization (CGH) microarray analysis; there
was no evidence that genomic aberrations were introduced during the process of establishing PARK2 iPSCs.
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pathway in PARK2 neurons.
Abnormal mitochondrial morphology and impaired
mitochondrial turnover in PARK2 iPSC-derived neurons
Increased oxidative stress (which affects anti-oxidant
defense systems) and mitochondrial dysfunction are impli-
cated in the pathogenesis of PD [1,13,21-23]. Furthermore,ROS accumulation causes both oxidative damage and
mitochondrial dysfunction in the substantia nigra (SN) of
parkin-deficient mice [7]. However, the exact mechanism
of mitochondrial pathogenesis associated with PARK2 is
controversial. For example, while Drosophila parkin
mutants show abnormal mitochondrial morphology,
parkin-knockout mice do not [7,24]. In addition, while a
greater degree of mitochondrial branching is observed in
Figure 2 Increased oxidative stress accompanied by activation of the Nrf2 pathway in PARK2 iPSC-derived neurons. (A) GSH levels were
significantly reduced in PARK2 (PA1, 9 and 22, and PB2, 18 and 20) iPSC-derived neurospheres compared with those in control A (YA9) and B
(WD39) neurospheres. (B, C) DCF fluorescence intensity in PARK2 (PA1, 9 and 22, and PB2 and 20) iPSC-derived neurons was significantly higher
than that in control A (B7) and B (WD39) neurons. (D, E) Immunoblot analysis of Nrf2 and NQO1 levels in iPSC-derived neurons from PA and PB.
Expression of Nrf2 and NQO1 in PARK2 (PA9 and PB2) iPSC-derived neurons was significantly higher than that in control A (YA9) and B (WD39)
neurons. Relative protein abundance was normalized to β-actin. ** indicates P < 0.01 (Mann–Whitney U-test). Data represent the mean and SEM
of at least three experiments for each group.
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morphology of the mitochondria in these cells has not been
characterized [25]. To investigate these mitochondrial
abnormalities in more depth, we performed a detailed mor-
phological analysis of mitochondria in PARK2 iPSC-derived
neurons using electron microscopy. Mitochondria in
PARK2 neurons from both patients showed a highly
electron-dense matrix and swollen mitochondrial cristae
within the inner mitochondrial membrane (IMM)
(Figure 3A, black arrowheads). The perikaryal volumedensity of the abnormal mitochondria was significantly
increased in PA and PB iPSC-derived neurons relative to
control clones (Figure 3B). Furthermore, the density of nor-
mal mitochondria decreased (Figure 3B). Importantly, both
abnormal and normal mitochondria were observed in
PARK2 neurons (Figure 3A, white arrowheads). Abnormal
mitochondria were observed in 87.8% of iPSC-derived neu-
rons from PA, and 79.5% of iPSC-derived neurons from PB.
These data indicated that abnormal mitochondrial
morphology was a feature of most PARK2 iPSC-derived
Figure 3 (See legend on next page.)
Imaizumi et al. Molecular Brain 2012, 5:35 Page 5 of 13
http://www.molecularbrain.com/content/5/1/35
(See figure on previous page.)
Figure 3 Dysregulation of mitochondrial homeostasis in PARK2 iPSC-derived neurons. (A) Electron micrographs of control A (B7), control B
(WD39) and PARK2 (PA9 and PB2) iPSC-derived neurons. Boxed areas are shown in the enlarged images to the right. Control mitochondria
showed a characteristically long, cylindrical profile with well-organized cristae, and the electron density of the matrix was relatively low (white
arrowheads). By contrast, increased electron density of the matrix was evident in PARK2 mitochondria (black arrowheads), and the cristae often
appeared swollen. As shown in PB2, some of the neurons contained both morphologically intact (white arrowheads) and abnormal (black
arrowheads) mitochondria. Furthermore, abnormal tubulovesicular structures (asterisks) were observed adjacent to the Golgi cisternae (G). (B) The
relative perikaryal volume of the abnormal mitochondria was significantly increased, and that of the normal mitochondria was decreased, in
PARK2 neurons compared with control neurons. (C) Double labeling for the IMM marker, ComplexIII coreI (CIII-Core I; magenta) and βIII-tubulin
(green) of control A (B7), control B (WD39) and PARK2 (PA9 and PB2) iPSC-derived neurons. The volume of the IMM area was reduced in control
neurons treated with CCCP, but not in PARK2 neurons treated with CCCP. Administration of Baf A1 rescued the CCCP-induced phenotype in
control neurons. (D) The CCCP/DMSO ratio in control A (B7 and YA9) and B (WD39) neurons was reduced after CCCP treatment. This reduction
was not observed in PARK2 (PA1, 9 and 22, and PB2 and 20) iPSC-derived neurons (black bars indicate CCCP/DMSO ratio; white bars indicate Baf
A1+CCCP/Baf A1 ratio). ** indicates P < 0.01 compared with the control; }} indicates P < 0.01 when comparing the black and white bars (Mann–
Whitney U-test). At least three experiments were performed for each group, with 5–36 cells quantified per experiment. Scale bars: a, 1 μm; c, 10
μm. Error bars represent the SEM. N.D., not detected.
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tubulovesicular structures were observed adjacent to
the Golgi cisternae in PARK2 iPSC-derived neurons
(Figure 3A). These abnormal mitochondrial and tubu-
lovesicular structures were not observed in PARK2
fibroblasts or in undifferentiated iPSCs (Additional file
5A and B). These histological abnormalities represent
novel PARK2-related neuronal pathologies.
PARKIN is involved in the mitochondrial fission/fusion
system and is recruited to depolarized mitochondria to
promote mitophagy [5,26-29]. In iPSC-derived neurons
containing a mutation in PINK1 (a protein kinase up-
stream of PARKIN), PARKIN is not recruited appropriately
to mitochondria [30]. We hypothesized that PARKIN-
deficient human neurons would show aberrant removal of
depolarized mitochondria. To examine the turnover of
damaged mitochondria, we treated iPSC-derived neurons
with carbonyl cyanide m-chlorophenyl hydrazine (CCCP),
which triggers the loss of mitochondrial membrane poten-
tial and results in the removal of damaged mitochondria.
The intensity of TMRE, a mitochondrial membrane
potential-dependent dye, clearly decreased in both control
and PARK2 iPSC-derived neurons treated with CCCP,
which indicated a reduced mitochondrial membrane po-
tential in both sets of neurons (Additional file 6). To deter-
mine the extent to which the damaged mitochondria were
eliminated, we measured the area of the IMM after CCCP
treatment. Compared with untreated cells, there was a
dramatic loss of IMM area in the treated control neurons,
but not in the treated PARK2 neurons (Figure 3C, left four
columns; Figure 3D, black bars). To assess whether lyso-
somes were involved in the CCCP-induced elimination of
mitochondria, we treated cells with Bafilomycin (Baf) A1,
an inhibitor of the vacuolar type H(+)-ATPase. Baf A1
attenuated the CCCP-dependent reduction in the IMM
area in control neurons (Figure 3C, right four columns;
Figure 3D, white bars). To confirm that the abnormal
turnover of damaged mitochondria was characteristic of
neuronal cells, PARK2 fibroblasts and undifferentiatediPSCs were treated with CCCP. CCCP-treated PARK2
fibroblasts and undifferentiated iPSCs exhibited the same
mitochondrial dynamics as CCCP-treated control cells
(Additional file 5C-E). Together, these data indicated aber-
rant degradation of mitochondria damaged by CCCP treat-
ment in PARK2 iPSC-derived neurons.
These results support a recently proposed working
model for PD, in which damaged mitochondria accumu-
late due to a disruption in PARKIN-mediated mitochon-
drial quality control [28]. The electron microscopy data,
which showed a mixture of abnormal and normal mito-
chondria, indicated that PARKIN-mediated mitochondrial
quality control is compromised, even in young PARK2
iPSC-derived neurons. In these cells, residual normal
mitochondria may have compensated for the damaged
ones. Thus, while our findings suggest that the PARKIN-
dependent mechanisms that regulate mitochondrial
homeostasis are disrupted in PARK2 cells, further detailed
analyses are required to fully understand the mechanism
underlying this disruption and the implications for PD.
Patient-specific accumulation of α-synuclein in PARK2
iPSC-derived neurons and its correlation with LB
formation
LBs are pathological neuronal inclusions composed princi-
pally of α-synuclein. They are typically associated with PD
and certain forms of dementia [1,13,31]. Although LBs are
generally thought to be absent from PARK2 patients
[1,13,31], rare cases of LB formation in the brains of
PARK2 patients have been reported recently [12,32,33].
The PARKIN protein co-localizes with LBs in some
patients with sporadic PD [34], and a functional interaction
between PARKIN and α-synuclein is indicated by both
in vitro and in vivo findings [35-37]. These results suggest
that PARKIN-pathway may contribute to LB formation in
PD patients.
We were able to conduct a histopathological analysis of
postmortem brain tissue from patient PA. Hematoxylin and
eosin staining of the SN revealed low levels of brown-black
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(Figure 4A and A’). Surprisingly, LBs accumulated in the
SN and other areas of the brain in patient PA (Figure 4B
and Table 2). Furthermore, α-synuclein and pα-synuclein
immunoreactive puncta and neurites were observed in the
areas where LBs were present (Figure 4B). TH/pα-synuclein
double-positive neurons were also detected in the SN
(Figure 4C). Of note, α-synuclein-positive/TH-negative or
pα-synuclein-positive/TH-negative neurons in the SN and
other areas of the brain tissue from patient PA’s brain were
observed (Table 2). These data suggested that α-synuclein
accumulated not only in TH+ neurons, but also in other
types of neurons. Postmortem tissue from the brain of the
father of patient PB was also examined. The father carried
a homozygous deletion of exons 6 and 7 of the parkin
gene (Figure 1B, Additional file 1B and 7A), similar to
patient PB. There was no evidence of LBs or α-synuclein-
positive neurons in the autopsied brain tissue of the father
(Figure 4D). Thus, since the genetic background of patient
PB and his father are likely to be very close (Additional fileFigure 4 Accumulation of LBs in the postmortem brain of
patient PA. (A–C) Immunohistochemical staining of postmortem
brain tissue from patient PA. (A) Low magnification image of a
midbrain section stained with hematoxylin and eosin (H&E). (A’)
High magnification image of the boxed area. Melanin levels were
reduced in most of the substantia nigra (SN). (B) (Left) High
magnification image of a midbrain section stained with H&E
showing the presence of Lewy bodies (LBs) in the SN. (Middle and
Right) α-synuclein-positive and pα-synuclein-positive cells in the SN.
(C) Confocal microscopy image of a TH (green) and pα-synuclein
(red) double-positive SN neuron and a projected merged image: pα-
synuclein accumulated in the TH-positive neuron. (D) Melanin levels
were reduced in most of the SN. No LBs or α-synuclein-positive
neurons were observed in postmortem brain tissue from the father
of patient PB. Scale bars: A, 1000 μm; A’, 350 μm; B, C, 50 μm; D,
100 μm.1B and 7A), these results are probably reflective of a spe-
cific phenotype of patient PB, which was different from
that in patient PA (Figure 4A-D).
To determine whether iPSC-derived neurons recapitu-
lated the in vivo phenotypes of the corresponding cell
donors, we next examined α-synuclein accumulation in
PARK2 iPSC-derived neurons. To rule out the possibility
that α-synuclein expression in undifferentiated PARK2
iPSCs was increased by multiplication of the SNCA gene,
genomic aberrations acquired during the process of iPSC
establishment, or by repeated passage of the cells, the
SNCA gene copy number in iPSCs was quantified by ge-
nomic qPCR. A comparison with control iPSCs showed
that iPSCs from both PA and PB carried the normal num-
ber of SNCA gene copies (Additional file 8A). Moreover,
immunostaining for α-synuclein did not reveal any in-
crease or decrease in α-synuclein protein levels in PARK2
iPSCs (Additional file 8B). As a control for LB forma-
tion, we generated iPSC-derived neurons from a 106-
year-old woman (designated Cent1-8), since previous
work suggested that aging is a predisposing factor for
LB formation in PD patients [31,38]. Since α-synuclein
was also expressed in non-neural cells, triple labeling
for α-synuclein, βIII-tubulin, and TH was performed to
ensure that only neurons were examined (Figure 5A,
asterisks). The proportion of α-synuclein-positive iPSC-
derived neurons that were also positive for βIII-tubulin
from PB was similar to that in the controls (including
Cent1-8); however, the proportion was significantly
higher in PA. These results were consistent with the
in vivo phenotypes of the cell donors based on analysis
of postmortem brain tissue (1629, 357, 805, 3747, and
4330 iPSC-derived βIII-tubulin+ neurons in control A,
control B, Cent1-8, PA and PB respectively; Figure 5A-C,
arrows and arrowheads). Thus, the increase in α-synuclein
expression levels seen in PARK2 iPSC-derived neuronsTable 2 LB type pathology in PA patient’s postmortem
brain
Brain area LB type pathology
Brainstem lesion IX-X +++
LC +++
SN ++
Basal forebrain/Limbic nbM ++
Amy ++
Ent +
Cing +
Neocortical T -
F -
P -
IX-X, motor cranial nerves IX-X; LC, Locus Coeruleus; SN, Substantia Nigra; nbM,
nucleus basal of Meynert; Amy, Amygdala; Ent, Entorhinal cortex; T, Temporal
lobe; F, Frontal lobe; P, Parietal lobe.
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associated with the disease phenotype.
The obvious LB-formation was observed in the postmor-
tem brain of PA patient, who showed a late onset at 61
years, corresponding to the enhanced α-synuclein accumu-
lation in the iPSC-derived neurons from the same patient.
Thus, it is likely that early-stage LB formation was recapitu-
lated in vitro in iPSC-derived neurons. Furthermore, the
present findings are consistent with recent work by several
groups, which suggest that the age of onset of PARK2 in
patients with LB formation (41 on average) is later than in
patients without LB formation (below 40) [12,32,33]. The
earlier onset in patient PB (at 28 years) than in PA (at 61
years) would be consistent with the finding of lower
α-synuclein accumulation in PB iPSC-derived neurons
compared with PA iPSC-derived neurons. On the other
hand, and in contrast to the observations of brain tis-
sue from PA, analysis of brain tissue from the father of
patient PB, in whom the onset of PD was 39 years of
age, revealed no evidence of LB formation (Figure 4D).
Importantly, PA iPSC-derived neurons showed signifi-
cantly more α-synuclein accumulation than PB iPSC-
derived neurons (Figure 5A and C). These results sug-
gest that the extent of α-synuclein accumulation is an
important factor in LB formation. Then, how can we ex-
plain the difference of α-synuclein accumulation between
PA and PB patients-derived neuronal cells? It is possible
that PA is a rare example of PARK2 complicated by spor-
adic PD. Although both PA and PB iPSCs showed a normal
SNCA gene copy number, it is possible that PA-derived
cells acquired an unknown gene mutation relating to LB
formation. Thus, we cannot rule out the possibility that
other factors may affect LB formation in PARK2 patients.
Further analyses will be required to identify these putative
factors. Although iPSC clones from sporadic and familial
PD patients were recently established [17,30,39-42], this
report is the first to demonstrate that the phenotype of
PD-specific iPSC-derived neurons replicates the in vivo
phenotype seen in postmortem brain tissue from the cor-
responding cell donor.
Conclusions
In summary, dysfunctional neuronal homeostasis (charac-
terized by increased oxidative stress and activation of the
Nrf2 pathway), impaired mitochondrial function, and
increased α-synuclein accumulation were observed in
PARK2 iPSC-derived neurons. These results indicate that
PARK2-associated phenotypes may appear soon after, or
possibly even before, the onset of PARK2. Detailed analyses
of PARK2 iPSC-derived neurons, particularly mature neu-
rons, to determine the time course of LB accumulation and
synaptic dysfunction will be of great interest. Such analyses
will further our understanding of the pathogenesis of
PARK2 as well as sporadic PD. The ultimate goal is thedevelopment and application of novel preventative therap-
ies for PD.
Materials & methods
Isolation of human skin fibroblasts and generation of
iPSCs
For control A, human dermal fibroblasts (HDFs) from the
facial dermis of a 36-year-old Caucasian female (Cell Appli-
cations Inc.) were used to establish iPSCs (201B7; Passage
20–29, YA9; Passage 15–24). The 201B7 iPSCs were kindly
provided by Dr. Yamanaka [15]. A skin-punch biopsy from
a healthy 16-year-old Japanese female obtained after written
informed consent (Keio University School of Medicine) was
used to generate the control B iPSCs (WD39; Passage
8–17). PA iPSCs (PA1, 9, and 22; Passage 10–19) and PB
iPSCs (PB1, 2, 18, and 20; Passage 8–17) were generated
from a 71-year-old Japanese female patient and a 50-year-
old Japanese male patient, respectively, using the same
methods used to generate control B iPSCs. The mainten-
ance of HDFs, lentiviral production, retroviral production,
infection, stem cell culture and characterization, and tera-
toma formation were performed as described previously
[14,15]. All of the experimental procedures for skin biopsy
and iPS production were approved by the Keio University
School of Medicine Ethics committee (Approval Number:
20-16-18) and Juntendo University School of Medicine
Ethics committee (Approval Number: 2012068). hESCs
(KhES-1; Passage 29–38 (kindly provided by Dr. Norio
Nakatsuji) were cultured on feeder cells in iPS culture
media [43].
In vitro differentiation of human iPSCs
Neural differentiation of iPSCs was performed as previously
described [44] with slight modifications (Okada et al.,
manuscript in preparation). Briefly, iPSC colonies were
detached from feeder layers and cultured in suspension as
EBs for about 30 days in bacteriological dishes. EBs were
then enzymatically dissociated into single cells and the
dissociated cells cultured in suspension in serum-free
media (MHM) [44] for 10 to 14 days to allow the formation
of neurospheres. Neurospheres were passaged repeatedly
by dissociation into single cells followed by culture in the
same manner. Typically, neurospheres between passages 3
and 8 were used for analysis. For terminal differentiation,
dissociated or undissociated neurospheres were allowed to
adhere to poly-L-ornithine- and fibronectin-coated cover-
slips and cultured for 10 days.
Immunocytochemical analysis of iPSCs and neurons
For immunocytochemical analysis, cells were fixed with
phosphate buffered saline (PBS) containing 4% paraformal-
dehyde (PFA) for 30 min at room temperature (RT). The
cells were analyzed by immunofluorescence staining using
antibodies to the following proteins: β-III-tubulin (1:1000,
Figure 5 α-synuclein accumulation in PARK2 iPSC-derived neurons. (A–C) Triple labeling for α-synuclein (red), tyrosine hydroxylase
(TH; cyan), and βIII-tubulin (green) along with Hoechst (blue) staining of control A (B7), control B (WD39), Cent1-8, and PARK2 (PA9 and PB20)
iPSC-derived neurons. (A) Arrows indicate α-synuclein+/TH+/βIII-tubulin+ neurons; arrowheads indicate α-synuclein+/TH-/βIII-tubulin+ neurons.
Note the presence of α-synuclein+/TH-/βIII-tubulin- non-neural cells (asterisks). (B) High magnification confocal projection image of an
α-synuclein (magenta)/βIII-tubulin (green) double-positive PA9 iPSC-derived neuron. (C) The proportion of α-synuclein+/βIII-tubulin+ neurons
relative to βIII-tubulin-positive neurons was significantly higher in PA (PA1, 9 and 22) iPSC-derived neurons than in control A (B7 and YA9), control
B (WD39) and Cent1-8 iPSC-derived neurons. Scale bars: A, 50 μm; C, 5 μm. ** indicates P < 0.01; * and } indicate P < 0.05 (Mann–Whitney
U-test). Data represent the mean and SEM of at least three experiments for each group.
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http://www.molecularbrain.com/content/5/1/35Sigma), NANOG (1:100, ReproCELL), OCT3/4 (1:200,
Santa Cruz Biotechnology), SSEA-4 (1:200, Millipore),
TRA-1-60 (1:200, Millipore), TH (1:100, Millipore), α-
synuclein (1:500, Invitrogen), pα-synuclein (1:1000, Wako),
cleaved-Caspase3 (1:500, Cell Signaling) and ComplexIII
(C-III)-core I (1:200, Invitrogen). Cells were washed with
PBS after incubation with the primary antibody, followed
by incubation with an Alexa Fluor 488-, Alexa Fluor 555-,
or Alexa Fluor 647-conjugated secondary antibody (1:500,
Invitrogen). Images were obtained using Apotome (Zeiss)
or LSM-710 confocal (Zeiss) microscopes.
PCR amplification of genomic DNA
Genomic DNA was purified from HDFs and iPSCs using
a DNeasy kit (Qiagen). The PCR conditions used have
been previously described [2,42].
Reverse transcription (RT)-PCR
RNA isolation and reverse transcription (RT)-PCR were
performed as previously described [44]. The amount of
cDNA was normalized to β-actin mRNA. Real-time RT-
PCR was performed on a ABI PRISM Sequence detection
System 7900HT (Applied BioSystems) using SYBR premix
ExTaq (Takara). Primers for the detection of Oct4, the
transgenes Oct4-tg, Sox2-tg, Klf4-tg and c-Myc-tg, and
MAO-A, and -B have been previously described [10,15].
Teratoma assay
To assess teratoma formation, iPSCs were injected into
the testis of 8-week-old NOD/SCID mice (OYG Inter-
national) as previously described [14]. Eight weeks after
transplantation, tumors were dissected and fixed with 4%
PFA in PBS. Paraffin-embedded tissue was sectioned and
stained with H&E. Images were obtained using a BZ-9000
(Keyence) microscope.
CGH array
Genomic DNA was restricted, labeled, and purified using
the Agilent Oligo CGH Microarray Kit (Agilent Techno-
logies) according to the manufacturer’s protocol. Labeled
genomic DNA was processed for hybridization on a 4x
180K microarray (Agilent Technologies). Processing was
performed as instructed by the manufacturer. The gen-
omic analysis was performed using Agilent Genomic
Workbench ver. 6.0 software (Agilent Technologies).
Metabolism assays
Reduced GSH levels were measured according to the kit
manufacturer’s protocol (GSH-Glo Glutathione Assay;
Promega). Chymotrypsin-like proteasome activity was
measured using a Cell-Based Proteasome-Glo Assay
according to the manufacturer’s instructions (Promega).
Briefly, neural cells (1.0 × 104) derived from neurospheres
were seeded in triplicate into a white 96-well plate (Nunc).Prepared reagent (100 μl) was added to each well. After
incubation for 10 min at RT, luminescence intensity was
recorded. ROS levels were determined by measuring
DCFH-DA fluorescence (Invitrogen). Briefly, neurons
were incubated with 5 μM DCFH-DA and Hoechst
(1:2000) for 30 min at 37°C, after which they were washed
with PBS and then incubated in differentiation media.
Fluorescence was measured by an In Cell Analyzer 2000
system (GE Healthcare Biosciences).
Protein analysis
Differentiated neurons were harvested in MAPK lysis buffer
containing proteinase inhibitor, and protein concentrations
were measured by BCA assay (Thermo Scientific). Samples
were diluted to yield equivalent protein concentrations and
then 4 μg was denatured by the addition of 4X sample
buffer (Invitrogen) supplemented with β-mercaptoethanol
followed by boiling. Samples (7 μl/lane) were loaded onto a
4–20% SDS-polyacrylamide gradient gel. Membranes were
incubated in blocking solution with the indicated primary
antibodies at 4°C overnight. Immunoreactive proteins were
detected with horseradish peroxidase (HRP)-conjugated
secondary antibodies and then visualized by chemilumines-
cence (Pierce, Rockford, IL, USA) according to the manu-
facturer’s instructions. Quantification of band intensities
was performed using an RAS4000 system. The primary
antibodies used were anti-NQO1 (1:1000, Abcam), anti-
NRF2 (1:1000, Santa Cruz Biotechnology) and β-actin
(1:5000, Cell Signaling).
CCCP and Baf A1 treatments
Neurons were cultured with 30 μM CCCP (Sigma-Aldrich)
or DMSO, with or without 5 μM Baf A1 (Sigma-Aldrich),
for 48 h. The cells were then fixed and stained for βIII-
tubulin and C-III Core I, and counterstained with Hoechst.
To quantify the IMM area of the neurons, the cytoplasmic
area was extracted as shown in Figure 3C. The C-III Core
I-positive signals within the extracted area were then con-
verted to gray-scale and digitized. The IMM area was quan-
tified from the digitized values using Image J software.
Tetramethylrhodamine ethyl ester (TMRE) staining
iPSC-derived neurons were incubated with 1nM TMRE
(Invitrogen) for 15 min at 37°C and then observed under
an Olympus IX81 microscope.
Electron microscopy
Cells were fixed with 2% glutaraldehyde/2% PFA in 0.1 M
phosphate buffer (PB) (pH7.2), post-fixed with 1% OsO4 in
0.1 M PB (pH 7.2), blocked and stained with a 2% aqueous
solution of uranyl acetate, dehydrated with a graded series
of ethanol, and then embedded in Epon 812 (TAAB).
Coverslips were detached and the embedded samples were
placed under a stereomicroscope to identify the cells of
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or UC7 ultramicrotome (Leica Microsystems) and then
stained with uranyl acetate and lead citrate. Samples
were observed with a Hitachi H7100 or HT7700 elec-
tron microscope.Morphometry
Morphometric analysis was used to measure the volume
density of mitochondria in the neuronal perikarya as pre-
viously described [45]. Briefly, electron micrographs of neu-
rons (n = 20, 23, 41, and 44 for control A (B7), control B
(WD39), PA9 and PB2, respectively) were obtained at a
magnification of ×7000. After enlarging to three times the
original magnification, point-counting was carried out to
determine the volume density using a double-lattice test
system with 1.5 cm spacing. Mitochondria were classified
as normal, abnormal, or undetermined. The abnormal
mitochondria were defined as those with irregularly
arranged cristae, or with a high electron-dense matrix. The
volume density (Vv) of each type of mitochondrion was
expressed as percent volume according to the following
formula: Vv = (Pi/Pt) × 100 (%), where Pi is the number of
points falling on each mitochondrial structure and Pt is the
number of points falling on the neuronal perikarya.Immunohistochemical analysis of autopsied brain tissue
The ethical committee of the Kitasato University School of
Medicine and Juntendo University School of Medicine
reviewed and approved the protocol for analysis of autop-
sied brain tissue. Patients and control subjects were
informed of the study and gave written informed consent.
Brain tissue from patient PA was obtained following her
death at age 72; brain tissue from the father of patient PB
was obtained when he died at age 70 [46]. Tissue was fixed
with 10% formalin and then embedded in paraffin. Mid-
brain sections (6 μm thick) were cut, deparaffinized with
xylene, and then rehydrated in ethanol. After being boiled
and treated with H2O2, sections were subjected to im-
munofluorescence staining with antibodies to the following
proteins: α-synuclein (1:500, Invitrogen), pα-synuclein
(1:1000, Wako), and TH (1:1000, Calbiochem). After was-
hing with PBS, sections were incubated with a biotinylated
secondary antibody (1:500; Vector Laboratories Inc.) at RT
for 1 hr followed by incubation with an avidin-biotin pe-
roxidase complex (Vector Laboratories Inc.) for 1 hr.
Immunoreactive proteins were visualized using 3,3-diami-
nobenzidine (DAB; Wako Pure Chemical Industries) and
nuclear fast red staining. For immunofluorescence, FITC-
conjugated and Cy3-conjugated secondary antibodies
(1:500; Jackson Immunoresearch Laboratories) were used.
Images were obtained using a BIOREVO (Keyence) and a
confocal laser-scanning LSM710 (Zeiss) microscope.Statistical analysis
Values represent the mean ± SEM. The Mann–Whitney
U-test was used to evaluate differences between groups. A
P value of < 0.05 was considered significant.
Additional files
Additional file 1: Genetic studies of family. (A) An arrow indicates PA
patient. (B) An arrow indicates PB patient. Filled circles and squares,
women and men with PARK2 mutation; Open circles and squares, normal
women and men; Diamond shapes, family members whose DNA
samples were not analyzed. Symbols with lines through them represent
the deceased.
Additional file 2: Characterization of control and PARK2 iPSCs. (A)
Control A (YA9), Control B (WD39), PA (PA9), and PB (PB2) iPSCs
expressed the pluripotency markers SSEA4 (red) and TRA1-60 (green).
Scale bar, 100 μm. (B) iPSCs established from patients PA (PA1, PA22) and
PB (PB1, PB18, and PB20) were positive for the pluripotency markers
Nanog (red), Oct4 (green), SSEA4 (red), and TRA1-60 (green). Scale bars:
phase images, 200 μm; immunofluorescence images, 100 μm. (C) Levels
of endogenous Oct4 mRNA in the generated iPSCs were similar to those
in KhES1 cells, a human embryonic stem cell (hESC) line [42]. Expression
levels were normalized to that of KhES1 (set as 1). (D) Cont A (YA9), Cont
B (WD39), PA (PA1, 9 and 22), and PB (PB1, 2, 18 and 20) iPSCs gave rise
to teratomas with all three germ layers, confirming pluripotency. Scale
bar, 100 μm. (E) Silencing of transgenes in control and PARK2 iPSC
clones. Expression levels were normalized to the positive control of
fibroblasts in cultures assayed 6 days after retroviral infection ( = 100).
Cont A, Control A; Cont B, Control B.
Additional file 3: Confirmation of parkin deletions and genomic
stability of PARK2 iPSCs using comparative genomic hybridization
(CGH) microarray analysis. (A) Exons 2–4 were deleted in the PA9 and
PA22 iPSC lines. Exons 6 and 7 were deleted in the PB2, 18, and 20 iPSC
lines. (B) Copy number profiles of whole chromosomes in PARK2 iPSCs
assessed by CGH microarray analysis revealed that no genomic
aberrations were introduced during the process of establishing PARK2
iPSCs.
Additional file 4: Expression level of MAO-A and -B showed no
difference among Control and PARK2 iPSC-derived neurons. (A,B)
qRT-PCR measurement of MAO-A and -B transcripts in PARK2 (PA (1, 9
and 22) and PB (1, 2 and 20)) iPSC-derived neurons showed no difference
compared to those in Cont A (B7 and YA9). ContA; Control A, ContB;
Control B.
Additional file 5: Healthy mitochondria in PARK2 fibroblasts and
iPSCs. (A, B) Electron micrographs of fibroblasts (upper panels) and iPSCs
(lower panels) from Control (Cont A and Cont B) and PARK2 patients (PA
and PB). Mitochondria in the fibroblasts and iPSCs from both groups
showed long, cylindrical profiles with well-organized cristae, and the
electron density of the matrix was relatively low (asterisks). Scale bar, 0.25
μm. Cont A, Control A; Cont B, Control B. (C) Fibroblasts were treated
with 30μM CCCP or DMSO for 48 h, followed by staining for CIII coreI
(magenta) to label the internal mitochondrial membrane (IMM) and
counterstaining with Hoechst (Ho, blue). Mitochondrial size decreased
after CCCP treatment in both Control (Cont A and Cont B) and PARK2
(PA and PB) fibroblasts. Scale bar, 20 μm. (D) iPSCs were treated with 30
μM CCCP or DMSO for 48 h and then stained for CIII coreI (magenta) to
label IMM, Oct4 (blue) to label iPSCs, and Hoechst (Ho, white).
Mitochondrial size in Control (Cont A (B7), Cont B (WD39)), and PARK2
(PA9 and PB2) iPSCs decreased after CCCP treatment. Scale bar, 20 μm
(E) CCCP/DMSO ratios in Control (Cont A (B7, YA9), Cont B (WD39)), and
PARK2 (PA9 and 22 and PB2 and 20) iPSCs (Mann Whitney U-test). Data
represent the mean and SEM (n > 3 for each group).
Additional file 6: Mitochondrial membrane potential after
CCCP treatment in control and PARK2 iPSC-derived neurons. (A)
iPSC-derived neurons were treated with 30 μM CCCP or DMSO for 48 h,
after which they were stained for the mitochondrial membrane potential
marker, TMRE. The intensity of TMRE (yellow) was clearly reduced in
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iPSC-derived neurons. Scale bar, 50 μm.
Additional file 7: Confirmation of parkin deletions carried by the
father of patient PB. (A) Deletion of exons 6 and 7 was confirmed in
blood samples from PB and the father of PB by PCR.
Additional file 8: α-Synuclein signals are not seen in PARK2 iPSCs.
(A) Quantitative genomic PCR analysis for SNCA exons 1 and 4
demonstrated a normal copy number in PARK2 (PA1, 9 and 22, and PB1,
2, 18 and 20) iPSCs. The copy number was the same as that observed for
Cont A (B7 and YA9) and Cont B (WD39). The SNCA gene copy number
was normalized to β-globin (HBB) and β2-microglobulin (B2MG). (B) iPSCs
were stained for α-synuclein (red), Oct4 (green; to label iPSCs) and
Hoechst (blue). No α-synuclein signals were observed in Cont A (B7 and
YA9), Cont B (WD39), or PARK2 (PA9 and 22, PB2 and 20) iPSCs. Scale bar,
50 μm.
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